| |
Screening-detected cancers
|
True interval cancers
|
False negatives
|
Minimal-sign cancers
|
Occult tumors
| |
|---|
| |
n = 1,297
|
n = 455
|
n = 224
|
n = 166
|
n = 103
|
P-value†
|
|---|
|
Estrogen receptor
|
1022 (82.5)*
|
283 (63.2 )*
|
178 (81.7)
|
114 (71.3)
|
84 (88.4)
|
<0.001
|
|
Missing values
|
58
|
7
|
6
|
6
|
8
| |
|
Progesterone receptor
|
775 (63.7)*
|
214 (48.2)*
|
128 (59.0)
|
86 (54.4)
|
60 (64.5)
|
<0.001
|
|
Missing values
|
81
|
11
|
7
|
8
|
10
| |
|
HER2
|
203 (21.9)
|
113 (29.1)*
|
44 (24.0)
|
31 (23.1)
|
11 (14.1)
|
0.018
|
|
Missing values
|
371
|
67
|
41
|
32
|
25
| |
|
p53
|
149 (22.7)
|
86 (36.6)*
|
23 (21.5)
|
27 (34.6)
|
17 (28.8)
|
<0.001
|
|
Missing values
|
641
|
228
|
117
|
88
|
44
| |
|
Ki67
|
381 (40.2)
|
169 (52.5 )*
|
83 (50.3)
|
50 (41.7)
|
26 (39.4)
|
0.001
|
|
Missing values
|
349
|
133
|
59
|
46
|
37
| |
- Number of cases and percentage of tumors with positive biomarker expression. *Standardized Pearson residuals with statistically significant deviation between observed and expected values. †P-values for comparison of characteristics among the five study groups were obtained by two-sided Chi-square test. HER2, human epidermal growth factor receptor 2.
